Gastrointestinal (GI) mucositis is a common side effect of intense chemotherapy to prepare patients for hematopoietic SCT. Measuring intestinal damage objectively remains difficult, and clinicians often rely on albumin levels as an indicator of GI mucositis, but citrulline might be a more specific marker, which has in the past been shown to correlate with clinical signs of GI mucositis. We evaluated the courses of albumin and citrulline following different conditioning regimens for SCT and studied their relatedness to the subsequent inflammatory response using C-reactive protein. Patterns of albumin and citrulline differed significantly between myeloablative and non-myeloablative conditioning regimens. After myeloablative regimens, decreasing citrulline levels preceded the occurrence of inflammation unlike albumin levels, which decreased thereafter. Albumin levels were greatly influenced by inflammation, confirming it to be a 'negative acute-phase protein', whereas citrulline levels were not. Citrulline appeared to be a better biomarker of GI mucositis than albumin. Measuring citrulline might prove useful in clinical decision making, in identifying GI mucositis, and it would also be of interest to see how it compares with other biomarkers in the setting of acute GI GVHD.
INTRODUCTION
Oral and gastrointestinal (GI) mucositis are common side effects of conditioning therapy for hematopoietic SCT. 1, 2 The degree of mucositis is determined by the nature and intensity of the chemotherapy, and is associated with adverse clinical and economic outcomes. 3 For example, GI mucositis results in abdominal pain and diarrhea, increases the risk of infection and has a role in GVHD. 4 GI mucositis is a manifestation of tissue damage to the GI mucosal barrier, and several tools have been employed to assess and grade the extent of damage induced by cytotoxic therapy. These include scoring the frequency and volume of diarrhea, measuring oral caloric intake, determining sugar permeability and 51 Cr-EDTA absorption. More recently, it has been shown that the concentration of citrulline in serum and plasma determines the degree of GI damage in conditions that are accompanied by gut failure. [5] [6] [7] Citrulline concentrations reflect the enterocyte mass and are not influenced by the presence of inflammation. 5, 8 Citrulline levels have also been shown to be an objective, reproducible and reliable means of determining GI mucositis in the setting of SCT, 9 with low citrulline levels correlated with the clinical scores of gut toxicity including diarrhea, and even seemed more reliable as stool volumes and frequency were influenced by oral intake and the use of drugs like opioid analgesics. 10, 11 In addition, citrulline levels were related to the occurrence of bacteremia, the postconditioning inflammatory response, as well as acute GvHD. 11, 12 Citrulline might be also useful as a predictor of inflammation as its decline usually precedes elevations in C-reactive protein (CRP).
However, in practice, physicians tend to rely on noting the presence of diarrhea. This is not specific and can have several causes besides GI mucositis. Moreover, we showed that citrulline and a daily gut score, that included diarrhea, corresponded well, but measuring the amino-acid allowed better monitoring of the progress of gut dysfunction as well as its extent.
Nonetheless, we wished to see whether serum albumin could also be used to monitor the toxicity resulting from chemotherapy, as this is determined routinely and is more familiar to clinicians. Despite its widespread use there are few reports on the clinical usefulness of monitoring albumin. 13, 14 Moreover, several factors can contribute to hypoalbuminemia of the SCT recipient, including the underlying disease, nutritional status, occurrence of acute and chronic inflammation, as well as protein-losing enteropathy resulting from mucositis. There is also evidence that albumin is, in fact, a 'negative acute-phase protein' as low concentrations correlate strongly with body temperature, elevated inflammatory markers including CRP, IL-6 and TNF-a and infection. 15, 16 Indeed serum albumin concentrations inform us about the general state of health and inflammatory status of SCT recipients, but we wished to explore its value for assessing GI mucositis per se.
Consequently, we evaluated the course of albumin and citrulline following conditioning treatment to prepare for a SCT, studied their relatedness to the inflammatory response and postconditioning GI damage, and investigated which marker is more valuable for assessing GI mucositis.
MATERIALS AND METHODS

Study population and conditioning
Forty-eight patients who had received an auto-SCT and 58 receiving an allo-SCT were included in this analysis. Data had been collected prospectively in all these patients, as they had participated in supportive care trials performed at our hematology department. Patients had given their informed consent to the prospective collection of data and plasma samples for investigational use. The local ethics committee (CMO Regio Arnhem-Nijmegen) approved these studies.
Demographic data and the conditioning regimens are depicted in Supplementary Table S1 and Supplementary Table S2 , respectively. All patients had been treated according to the same protocol. 12, 17 All patients receiving myeloablative conditioning were managed with a central venous catheter. In those patient total parental nutrition commenced when patients had insufficient oral intake for 48 h or more. Gut infections had been excluded in patients included in this analysis.
The sampling had been performed from the start of conditioning (day 1, Figure 1 ) until discharge. Owing to differences in length of stay, the period of sampling was different among conditioning regimen, being 18, 22, 30, 25 and 22 days for high-dose melphalan (HDM), BCNU/etoposide/cytarabine/ melphalan (BEAM), idarubicin/cyclophosphamide/total body irradiation (IdaCyclo-TBI), cyclophosphamide/anti-thymocyte globulin/total body irradiation (Cyclo-ATG-TBI) and cyclophosphamide/fludarabine (Cyclo-Flu), respectively. Because the conditioning started 12 days before SCT in Ida-Cyclo-TBIconditioned patients the follow-up was considerably longer. The period of sampling ended in most patients at full engraftment, that is on average 14 days post SCT. The period did not include episodes with acute GVHD, which occurred later. CRP had been measured daily and albumin twice weekly and samples of plasma had been collected thrice weekly and stored at À 80 1C for later determination of citrulline. Planned data collections were achieved most of the time, with no more than 5% missing samples (CRP 93/2328 (4%), albumin 36/699 (5%), and citrulline 48/1054 (4.5%)).
Unfortunately, clinical data on intestinal mucositis, in this case diarrhea, were not available for all patients. However, as mentioned earlier, studies have shown citrulline levels to correlate with clinical gut toxicity and an even more objective and reliable marker than measuring diarrhea. 10 CRP, albumin and citrulline Hypoalbuminemia was defined according to the CTC version 3.0 criteria by any concentration below 30 g/L (http://www.eortc.be/services/doc/ctc/ ctcaev3.pdf).
CRP concentrations X50 mg/L were considered a significant rise from baseline (normal value o5 mg/L). 18 CRP was chosen over cytokines as measurements are rapid, cheap and easy, and CRP levels correlated with pro-inflammatory cytokines such as IL-6 and IL-8. The time course of events was related to the start of conditioning therapy, designated as day 1.
Citrulline concentrations were determined by a standard procedure for determining amino acids using HPLC with mass-spectometry detection. 12 Citrulline levels below 10 mmol/L were deemed to indicate hypocitrullinemia, and regarded as reflecting severe GI mucositis. 5 
Statistical analysis
We graphically described the development over time of three outcome measures (citrulline, CRP and albumin) in four conditioning regimen groups (HDM and BEAM were analyzed together). We calculated for each day the mean of the observed values and showed the course over time of these means by connecting the values with straight line segments.
Missing values were dealt with by using all data points and applying the Loess smoother with smoothing parameter of 30%. 19 At each point in the data set a straight line was fitted to a subset of the data consisting of the 30% nearest neighbors with respect to the time axis. This regression line was fitted using weighted least squares, giving more weight to points near the point being estimated and less weight to points further away. The value of the regression function for the point was then obtained by evaluating the local regression line using the value of time after transplant for that data point. The fit was complete after regression function values had been computed for all data points.
We defined three types of events; citrulline p10 mmol/L, CRP X50 mg/L and albumin p30 g/L, and distinguished between six possible patterns of first occurrences of these events. We evaluated the differences in distribution of patterns between four conditioning regimen groups using Fisher's exact test or, if needed, a Monte-Carlo approximation using 10 000 samples.
RESULTS AND DISCUSSION
Time course of albumin and citrulline after myeloablative conditioning Sixty-nine patients received a myeloablative conditioning regimen to prepare for an auto-SCT (HDM/BEAM) and matched related donor allo-SCT (Ida-Cyclo-TBI). The pattern of citrulline, CRP and albumin are shown in Figures 1a and b . Early after the start of conditioning there was a rapid decline in citrulline concentrations, which reached a level below 10 mmol/L on day 10. This converged with the start of a systemic inflammatory response shown by a rise in CRP concentrations, starting around day 10-11 and reaching 50 mg/L by day 12. Consequently, the decline in citrulline preceded the inflammatory response, indicating that GI damage induces the inflammatory response seen after conditioning. 12 The course of albumin levels was different with the gradual descent lagging behind that of citrulline (Figure 1a and b) reaching levels of p30 g/L on day 13, hence 3 days after the nadir of citrulline had been reached and after the inflammatory response had commenced. This suggests that hypoalbuminemia did not precede but rather followed the occurrence of inflammation induced by GI damage.
Time courses of albumin and citrulline after myeloablative conditioning containing anti-thymocyte globulin The course of events was different for the group of 21 patients who had received ATG in their myeloablative conditioning regimen for a matched unrelated donor SCT. The course of citrulline was similar, but now albumin levels declined with levels approaching 30 g/L already on day 6 (Figure 1c ). This coincided with an inflammatory response (day 3), resulting from cytokinerelease induced by ATG, which resulted in the development of fever in most patients. 20 Hereafter, the decline in albumin halted and levels remained rather constant until day 12, following which, there was a progressive decline as seen in the other MA regimens coinciding with the inflammation, resulting from intestinal damage and producing a second peak of CRP from day 11-12 ( Figure 1c ).
Time courses of albumin and citrulline after non-myeloablative conditioning Only 11 patients had received a non-myeloablative regimen. Nevertheless, less damage was expected as the chemotherapy was less mucotoxic and this was reflected in a limited and shortlived decline in citrulline levels with only a few patients experiencing hypocitrullinaemia. There was no inflammation attributable to GI damage. An early modest rise in CRP in some cases coincided with the administration of chemotherapy, and the second rise in CRP was mostly late occurring during engraftment reaching modest levels below 50 mg/L. 12 Four patients had a significant rise above 50 mg/L; two during engraftment, one due to a thrombophlebitis and another due to pneumonia. The decline in albumin levels was less pronounced although most patients reached levels below 30 g/L, but in contrast with what was seen for MA regimens, this did not occur simultaneously with a rise in CRP.
Albumin and citrulline levels are not equal as biomarkers of GI mucositis Additional statistical analysis confirmed the observed differences in the pattern of post-conditioning events among the groups (Figure 1 , Monte-Carlo approximation of Fisher's exact test, Po0.0001). There was no difference in patterns of events between groups A and B (P ¼ 0.42), but there were differences in pattern between C and A/B, D and A/B, and C and D (with P values based on Fisher's exact tests: o0.0001, 0.006 and 0.003, respectively). These differences are further illustrated graphically in Figure 2 . Following HDM/BEAM and Ida-Cyclo-TBI, citrulline levels declined before or at the time CRP levels became elevated and albumin levels declined thereafter. Following ATG-Cyclo-TBI, a regimen considered equally mucotoxic, the course of albumin but not citrulline was very different. The first peak in CRP levels preceded a decline in albumin levels, which was then followed by a second peak in CRP levels that coincided with the development of hypocitrullinaemia and a further decline in albumin levels. Following Cyclo-Flu, the attenuated GI damage precluded the marked hypocitrullinaemia and the corresponding inflammation in most cases. Albumin levels did not correspond to citrulline levels as these were already rising, whereas albumin levels were decreasing. Also the relationship between the occurrence of hypoalbuminemia and inflammation was less clear.
Hence, it seems fair to conclude that albumin and citrulline levels are not equal with regard to measuring GI mucositis. Citrulline follows a distinctive course that is clearly different for myeloablative and non-myeloablative regimens, which is almost certainly due to the mucotoxicity induced. The variation in citrulline concentrations was also less and the course of levels more consistent than was found for albumin. Moreover, citrulline can be considered a more reliable marker of GI damage because it is a very specific biomarker of enterocyte mass. 5, 9 By contrast, albumin levels appear mainly influenced by the occurrence of inflammation that resulted either from the host response to GI damage, the occurrence of infection or to the cytokines released by the conditioning therapy, particularly that containing ATG. The decline in albumin levels seen was not likely to be the result of malnutrition, as hypoalbuminemia occurred early after the start of conditioning therapy when the food intake is still adequate for most patients. 21 Dynamic changes in albumin levels are mostly owing to changes in catabolic rate and extra-vascular shift (capillary leakage) and not to malnutrition, as albumin has an estimated t 1,2 of 20 days. [21] [22] [23] Albumin decline after day 12 might be the result of the loss of proteins from the damaged GI tract as has been suggested for GVHD, and not solely from extra-vascular shift (capillary leakage) seen with inflammation. Nevertheless, the decline occurred late, sometime after GI damage and the related inflammatory response had already occurred. Hence, hypoalbuminaemia following SCT might be better regarded as a 'negative acute-phase response' or a late sequela of GI mucositis that comes with protein loss. Whichever is the case, citrulline levels appear a better biomarker of GI damage resulting from chemotherapy and radiotherapy than albumin. As citrulline is a better biomarker of GI damage, and may even be a suitable surrogate marker, it would be of particular interest to see how useful a biomarker it is to score and measure GVHD that involves the GI tract. Albumin has been shown to be a biomarker of GI GVHD, as it correlates with its severity, 24, 25 but this might be confounded by the inflammatory response that occurs with GVHD.
In conclusion, citrulline provides a better biomarker of chemotherapy and radiotherapy-induced GI mucositis, than does albumin. Determining citrulline levels might prove useful in helping decide whether and when therapeutic and nutritional interventions are necessary for patients treated with intensive chemotherapy and radiotherapy. 
